Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mallinckrodt
Biotech
Silence takes back 2 complement programs from Mallinckrodt
Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt Pharmaceuticals.
Annalee Armstrong
Mar 28, 2023 10:42am
FDA approves Mallinckrodt's regenerative skin burn graft
Jun 15, 2021 5:18pm
FDA rejects Mallinckrodt's kidney drug over risk-benefit doubts
Sep 14, 2020 8:25am
Mallinckrodt's kidney failure med squeaks by FDA panel 8-7
Jul 15, 2020 6:27pm
FDA staff question endpoint for Mallinckrodt's terlipressin
Jul 14, 2020 12:28pm
The top 15 biopharma licensing deals of 2019
Mar 23, 2020 11:00am